- Refractory Hepatic Hydrothorax in Chronic Hepatitis C Controlled by Direct-acting Antivirals
-
Kim MH, Kim DK, Eun HS, Rou WS, Kim SH, Lee BS
- KMID: 2471149
- Korean J Gastroenterol.
- 2020 Feb;75(2):98-102.
- doi: 10.4166/kjg.2020.75.2.98
Hepatic hydrothorax is a transudative pleural effusion that complicates advanced liver cirrhosis. Patients refractory to medical treatment plus salt restriction and diuretics are considered to have refractory hepatic hydrothorax and... -
- CITED
-
- Close
- SHARE
-
- Close
- Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease
-
Kim SU, Jeon MY, Lim TS
- KMID: 2469909
- Korean J Gastroenterol.
- 2019 Dec;74(6):341-348.
- doi: 10.4166/kjg.2019.74.6.341
BACKGROUND/AIMS: The utility of asialo-α1-acid glycoprotein (AsAGP) for assessing the fibrotic burden is unknown. This study examined the diagnostic performance of the AsAGP level for advanced liver fibrosis or cirrhosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B
-
Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU
- KMID: 2467249
- Clin Mol Hepatol.
- 2019 Dec;25(4):390-399.
- doi: 10.3350/cmh.2018.0103
BACKGROUND/AIMS: A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate nodules detected on computed tomography (CT) (Rad(CT) score) in patients with chronic hepatitis B (CHB)-related cirrhosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B
-
Kim GA, Shim JJ, Lee JS, Kim BH, Kim JW, Oh CH, Oh CM, Oh IH, Park SY
- KMID: 2463800
- Yonsei Med J.
- 2019 Dec;60(12):1203-1208.
- doi: 10.3349/ymj.2019.60.12.1203
Little is known about the benefits of statin use on liver cancer mortality among patients with chronic hepatitis B (CHB) considering hypercholesterolemia and obesity. A nationwide retrospective cohort study was... -
- CITED
-
- Close
- SHARE
-
- Close
- New Biomarkers of Chronic Hepatitis B
-
Mak LY, Seto WK, Fung J, Yuen MF
- KMID: 2464306
- Gut Liver.
- 2019 Nov;13(6):589-595.
- doi: 10.5009/gnl18425
Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis... -
- CITED
-
- Close
- SHARE
-
- Close
- New Potential Therapies for Chronic Hepatitis B
-
Yoo SH, Kwon JH
- KMID: 2464185
- Korean J Gastroenterol.
- 2019 Nov;74(5):267-273.
- doi: 10.4166/kjg.2019.74.5.267
A HBV infection is a dynamic disease and long-term liver inflammation contributes to the development of liver cirrhosis and hepatocellular carcinoma. Currently available nucleos(t)ide analogues and pegylated interferon are effective... -
- CITED
-
- Close
- SHARE
-
- Close
- Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients
-
Yoon EL
- KMID: 2464184
- Korean J Gastroenterol.
- 2019 Nov;74(5):258-266.
- doi: 10.4166/kjg.2019.74.5.258
Improved management of chronic hepatitis B patients with oral nucleos(t)ide analogues has increased the number of these patients who are getting older and have other accompanying comorbidities. These comorbidities frequently... -
- CITED
-
- Close
- SHARE
-
- Close
- Natural History and Treatment Indications of Chronic Hepatitis B
-
Sinn DH
- KMID: 2464182
- Korean J Gastroenterol.
- 2019 Nov;74(5):245-250.
- doi: 10.4166/kjg.2019.74.5.245
HBV is the most common etiology of both liver cirrhosis and hepatocellular carcinoma in Korea. Despite much progress made, the currently available antiviral therapies cannot eradicate or eliminate this virus.... -
- CITED
-
- Close
- SHARE
-
- Close
- Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity
-
Wu S, Tu R, Liang X
- KMID: 2464512
- Ultrasonography.
- 2019 Oct;38(4):327-335.
- doi: 10.14366/usg.18071
PURPOSE: This study was conducted to investigate whether the presence of patchy echogenicity in the liver of patients with chronic hepatitis B (CHB) is predictive of liver stiffness. METHODS: A total... -
- CITED
-
- Close
- SHARE
-
- Close
- What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
-
Kim JW
- KMID: 2460926
- J Korean Med Sci.
- 2019 Oct;34(41):e277.
- doi: 10.3346/jkms.2019.34.e277
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B
-
Choi EJ, Kim JH, Han MS
- KMID: 2458680
- Lab Med Online.
- 2019 Oct;9(4):210-217.
- doi: 10.3343/lmo.2019.9.4.210
BACKGROUND: Discrepancies in the results between hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA levels pose difficulties in the management of chronic hepatitis B (CHB). This study aims... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
-
Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU
- KMID: 2459790
- Clin Mol Hepatol.
- 2019 Sep;25(3):283-293.
- doi: 10.3350/cmh.2018.0054
BACKGROUND/AIMS: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP)... -
- CITED
-
- Close
- SHARE
-
- Close
- How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?
-
Yu JH, Lee JW
- KMID: 2459789
- Clin Mol Hepatol.
- 2019 Sep;25(3):280-282.
- doi: 10.3350/cmh.2018.0104
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
-
Na SK, Song BC
- KMID: 2459785
- Clin Mol Hepatol.
- 2019 Sep;25(3):234-244.
- doi: 10.3350/cmh.2018.0108
Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
-
Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK
- KMID: 2458512
- Gut Liver.
- 2019 Sep;13(5):549-556.
- doi: 10.5009/gnl18432
BACKGROUND/AIMS: Patients with Hansen’s disease are the most vulnerable to hepatitis C. However, no data on the treatment efficacy of direct-acting antiviral agents (DAAs) are available in this group. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C
-
Jun BG, Park EJ, Lee WC, Jang JY, Jeong SW, Kim YD, Cheon GJ, Cho YS, Lee SH, Kim HS, Lee YN, Kim SG, Kim YS, Kim BS
- KMID: 2457022
- Korean J Intern Med.
- 2019 Sep;34(5):989-997.
- doi: 10.3904/kjim.2017.322
BACKGROUND/AIMS: This study was conducted to clarify the sustained virological response (SVR) prediction ability of baseline and treatment-related factors in patients with chronic hepatitis C virus (HCV) infection. METHODS: This retrospective... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice
-
Song JE, Lee CH, Kim BS
- KMID: 2457310
- Korean J Intern Med.
- 2019 Jul;34(4):802-810.
- doi: 10.3904/kjim.2019.037
BACKGROUND/AIMS: The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear. We aimed to evaluate the long-term efficacy of... -
- CITED
-
- Close
- SHARE
-
- Close
- Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
-
Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG
- KMID: 2457309
- Korean J Intern Med.
- 2019 Jul;34(4):794-801.
- doi: 10.3904/kjim.2017.368
BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV)... -
- CITED
-
- Close
- SHARE
-
- Close
- Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?
-
Heo NY
- KMID: 2453262
- Korean J Gastroenterol.
- 2019 Jul;74(1):66-67.
- doi: 10.4166/kjg.2019.74.1.66
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C
-
Lee JH, Cho J, Kim J, Uh Y, Youn KJ
- KMID: 2450840
- Lab Med Online.
- 2019 Jul;9(3):153-160.
- doi: 10.3343/lmo.2019.9.3.153
BACKGROUND: Liver fibrosis evaluation is an important issue in chronic liver disease patients. We aimed to develop noninvasive liver fibrosis biomarkers based on transient elastography (TE, FibroScan®) through retrospective review... -
- CITED
-
- Close
- SHARE
-
- Close
